|
|
| Antibodies against gp120 may induce protection against HIV |
| |
| August 29, 2008, 4:38AM |
|
| In the closing hours of the 17th International AIDS Conference in Mexico City (3-8 August 2008), researchers reported that catalytic antibodies against the HIV envelope protein gp120 may prevent HIV infection during sexual intercourse when used as a microbicide. Read more in the Washington Post editorial by David Brown. |
| |
| Click here to view original article online or to download pdf |
|
| |
| NIAID will not move forward with the PAVE 100 HIV vaccine trial |
| |
| July 18, 2008, 1:57AM |
|
| The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has determined that the HIV vaccine study known as PAVE 100 will not be conducted. However, NIAID will entertain a proposal for an alternative study about this vaccine candidate. |
| |
| Click here to view original article online or to download pdf |
|
| |
| NIAID creates HIV Vaccine Discovery Branch: it is time for sinergy |
| |
| July 8, 2008, 2:06AM |
|
| The National Institute of Allergy and Infectious Diseases (NIAID) has created the “HIV Vaccine Discovery Branch” to promote sinergy between basic HIV researchers and vaccine designers. Read about its main duties and targets in the NIH News bullettin. |
| |
| Click here to view original article online or to download pdf |
|
| |
| PAVE’s trial rebirthing |
| |
| June 30, 2008, 5:12AM |
|
| After the STEP trial failure, the Partnership for AIDS Vaccine Evaluation (PAVE) 100 decided to step behind for making the PAVE 100 trial move forward. The PAVE 100 trial was conceived as a phase 2b trial of about 8500 participants in 13 countries, using a DNA prime made up of 6 plasmid constructs (gag, pol, and nef, plus env from clade A, B, and C virus) followed by an adenovirus vector 5 (Ad5) booster). According to Scott Hammer, Principal Investigator, the PAVE 100 trial vaccine product and administration schedule would remain the same, but the study population would be greatly restricted, volunteers would be studied much more intensely, and emphasis will be shifted from product development toward basic research. |
| |
| Click here to view original article online or to download pdf |
|
| |
| HIV vaccine failures: wrong immune response |
| |
| June 26, 2008, 2:38AM |
|
| The recent HIV vaccine failures have caused the need of designing novel vaccine approaches to HIV infection. This was the focus of a seminal meeting organized by The National Institute of Allergy and Infectious Disease (NIAID), which has been held in Bethesda, MD, USA on March 25, 2008. In a “Comment” published in the June issue of The Lancet, Dr. Boasso A., Dr. Shearer G.M. and Prof. Clerici. M. ask themselves why the traditional immunisation-memory-response paradigm seems not work in the case of an HIV vaccine. |
| |
| Click here to view original article online or to download pdf |
|
| |
| 25 Years of HIV – the challenge |
| |
| May 29, 2008, 3:39AM |
|
| “The HIV/AIDS catastrophe has been one of the defining features of the past quarter of a century. [...] Much remains to be accomplished in the global fight against HIV”. In the words of Anthony S. Fauci is the thought of many scientists, who are hardly committed in the challenge of an HIV/AIDS vaccine development. |
| |
| Click here to view original article online or to download pdf |
|
| |
| HIV/AIDS vaccines: a point of view over 25 years of failures |
| |
| May 15, 2008, 2:49AM |
|
| In the quarter century since the discovery of HIV, Dr. Alan Bernstein, Executive Director of the Global HIV Vaccine Enterprise, tries to analyse the failure of HIV vaccine approaches according to another perspective. Read his editorial featured in May 9, 2008 edition of Science. |
| |
| Click here to view original article online or to download pdf |
|
| |
| Study by George Institute for International Health suggest that an AIDS vaccine is possible. |
| |
| April 17, 2008, 3:28AM |
|
| IAVI has commissioned the George Institute for International Health to undertake a study. The views of over 30 stakeholders including public sector researchers, biotechnology firms, large pharmaceutical companies, and investors are due to be published later this year. Preliminary findings suggest that interviewees find scarce and fragmented funding of European academic research an important limitation for both the quality and quantity of innovative ideas. Results also suggests that collaborations between public research labs and biotech firms are a much needed model for mobilising biotech involvement in AIDS vaccine R&D, so long as the industry contribution is adequately funded and collaborations involve relatively small numbers of partners.
For further information contact IAVI Secretariat.
|
| |
| Click here to view original article online or to download pdf |
|
| |
| "Will there ever be an AIDS vaccine?" |
| |
| January 21, 2008, 1:44AM |
|
| “Will there ever be an AIDS vaccine?” That is the question formulated by Dr. Robert Steinbrook in his editorial published by NEJM on December 2007 issue. |
| |
| Click here to view original article online or to download pdf |
|
| |
| AIDS Clinical Care published the Top HIV/AIDS stories of 2007 |
| |
| January 21, 2008, 1:43AM |
|
| Have a perspective on the 2007’s most important stories in HIV clinical care and research with the “Top HIV/AIDS Stories of the year” published by AIDS CLINICAL CARE |
| |
| Click here to view original article online or to download pdf |
|
| |
| An editorial by “Nature Medicine” tries to analyse in depth the situation and esorts researchers to learn from mistakes. |
| |
| January 5, 2008, 2:06AM |
|
| It is a common belief among researchers that a vaccine is the only possible way to stop the AIDS pandemic in the world. Yet, the failure of some advanced (II, III) HIV vaccine clinical trials has renewed the skepticism about the possibility of developing an effective vaccine against HIV/AIDS. An editorial by “Nature Medicine” tries to analyse in depth the situation and esorts researchers to learn from mistakes. |
| |
| Click here to view original article online or to download pdf |
|
| |
| Report of the last Global HIV Vaccine Enterprise workshop held in May 2007, discusses new approaches to design vaccines that induce viral neutralizing antibody responses. |
| |
| January 5, 2008, 2:05AM |
|
| At the last Global HIV Vaccine Enterprise workshop, which was held in May 2007, scientists discussed new approaches to design vaccines that induce viral neutralizing and other protective antibody responses, trying to identify key scientific issues, gaps, and opportunities that have emerged in the last few years, to make recommendations that Enterprise stakeholders should consider to plan new activities. The results of the workshop were published (PloS Medicine) in December 2007 in the summary report, entitled: “Antibody-Based HIV-1 Vaccine: Recent Developments and Future Directions”. |
| |
| Click here to view original article online or to download pdf |
|
| |
| Oct. 22-24, 2007: AVIP meeting in S.Africa |
| |
| January 5, 2008, 2:04AM |
|
| On October 22-24 the AVIP consortium held its annual plenary meeting in Johannesburg, S.Africa, with participation of its Scientific Advisory Board and Monitoring Committee. During the two day meeting participants presented the results of research to the Advisory Board members for their recommendations. The meeting was also an occasion to further discussions and planning with S.African scientists for the Phase II clinical trials to be launched in the first half of 2008. |
| |
| Click here to view original article online or to download pdf |
|
| |
|
| News Editor Login |